1. Wilson MR (19 December 2012). "Reg Watch". The Hill. Archived from the original on 20 March 2013.
2. "Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV". 19 December 2012.
3."Department Of Justice Drug Enforcement Administration 21 CFR Part 1308, Placement of Lorcaserin into Schedule IV". 8 May 2013.
4. Greenway FL, Shanahan W, Fain R, Ma T, Rubino D (October 2016). "Safety and tolerability review of lorcaserin in clinical trials". Clinical Obesity (Review). 6 (5): 285–95. doi:10.1111/cob.12159. PMID 27627785.
5. "BELVIQ and BELVIQ XR HCP Home Page". www.belviqhcp.com. Archived from the original on 16 June 2016.